Meghana Keshavan

Meghana Keshavan

Meghana has spent the last year-and-a-half writing about biotech and healthcare for the San Diego Business Journal. Previously, she's worked for Reuters, Crain’s Detroit Business, the Detroit Free Press and WDET, a Detroit-based National Public Radio affiliate. Meghana studied biochemistry and molecular biology at Penn State University and spent five years as a self-described "research peon in a schizophrenia genetics lab."

Follow Meghana Keshavan: Twitter |


GeneSegues gets gov’t contract to develop a topical vaccine for Venezuelan encephalitis

GeneSegues gets gov’t contract to develop a topical vaccine for Venezuelan encephalitis

December 19, 2014 3:29 pm by | 0 Comments

Minneapolis vaccine developer GeneSegues Therapeutics has a new government contract to develop a DNA vaccine against Venezuelan equine encephalitis virus – an infectious disease that has the potential to be used as…


Vical pushing ahead with genital herpes vaccine trials

Vical pushing ahead with genital herpes vaccine trials

December 19, 2014 6:00 am by | 0 Comments

Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 1/2 trial of its Vaxfectin genital herpes vaccine – a therapeutic inoculation that’s melded vaccine…



The best biotech and biopharma tweeters on Twitter

The best biotech and biopharma tweeters on Twitter

December 18, 2014 8:59 pm by | 3 Comments

It seems pretty spot on. Compiled by Jenna Dobkin, commissioned by NEMUS Biosciences:


Purdue spinout developing drug that cuts down neurotoxin associated with multiple sclerosis

Purdue spinout developing drug that cuts down neurotoxin associated with multiple sclerosis

December 18, 2014 7:27 pm by | 0 Comments

MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences. Purdue spinout Neuro Vigor is developing a multiple sclerosis therapeutic…


Cleveland Clinic spinout’s 3D surgical platform could reduce radiation exposure during operations

Cleveland Clinic spinout’s 3D surgical platform could reduce radiation exposure during operations

December 18, 2014 2:04 pm by | 0 Comments

A Cleveland Clinic spinout will give surgeons a “GPS-like” tool to navigate a patient’s insides while they’re on the operating table, so as to improve the efficacy and safeness of…


Why biotech CEOs must carry that risk-taking gene

Why biotech CEOs must carry that risk-taking gene

December 18, 2014 6:00 am by | 1 Comments

There’s an evolutionary benefit to being a risk-taker: Our loincloth-adorned forebears needed, after all, a fearless leader to explore uncharted, food-filled territory. In today’s society, who possesses these genes? Biotech leaders…


The business case for Sean Parker’s $24M gift to Stanford for allergy research

The business case for Sean Parker’s $24M gift to Stanford for allergy research

December 17, 2014 12:01 am by | 4 Comments

Tech entrepreneur Sean Parker just pledged $24 million to Stanford University to set up a new institute for allergy research, and it comes at an important time: We might not be too…



Louisville startup designing pessary-like device to head off preterm labor

Louisville startup designing pessary-like device to head off preterm labor

December 16, 2014 5:43 pm by | 0 Comments

Louisville startup MB Device is developing tool to monitor a pregnant woman’s cervix to determine if she’s going into labor. It’s meant for those at high risk for preterm labor –…


Insightra gets $12M for hernia repair prosthesis

Insightra gets $12M for hernia repair prosthesis

December 16, 2014 6:00 am by | 0 Comments

An FDA-cleared surgical prosthesis that treats hernias has attracted some recent capital, ostensibly so the company – called Insightra Medical – can expand its scope abroad. The Irvine, California-based company…


What to expect when you’re expecting… a lot out of the JP Morgan Healthcare Conference

What to expect when you’re expecting… a lot out of the JP Morgan Healthcare Conference

December 15, 2014 6:00 am by | 0 Comments

Four weeks from today, many of us will be dallying at the JP Morgan Healthcare Conference that’s held Jan. 12-15 in San Francisco. Now’s the time to start planning – what…


Topol and San Diego coroner turn to genetics to understand sudden, unexplained death

Topol and San Diego coroner turn to genetics to understand sudden, unexplained death

December 14, 2014 12:00 pm by | 0 Comments

Despite all our tricks of medical deduction, sometimes a death can just be left unexplained: No heart attack, no stroke, no slip of a cyanide pill…The post-mortem yields nothing, and families…


Could algae blooms cause Lou Gehrig’s Disease?

Could algae blooms cause Lou Gehrig’s Disease?

December 13, 2014 3:40 pm by | 3 Comments

Researchers are now linking some ALS incidence with folks who live near large bodies of water, a new piece in Scientific American points out. It writes: About five years ago, doctors at…


Does drug pricing reflect innovation? The evidence suggests not – and other 2015 biotech trends

Does drug pricing reflect innovation? The evidence suggests not – and other 2015 biotech trends

December 12, 2014 7:18 pm by | 1 Comments

A rich new Credit Suisse report, “Global Biotechnology – An Outlook for 2015,” was flush with cool data about trends in the biotech industry. The analysis lists out 10 key…


Cornerstone’s cancer metabolism drugs sap tumor cells’ energy to replicate

Cornerstone’s cancer metabolism drugs sap tumor cells’ energy to replicate

December 12, 2014 6:00 am by | 0 Comments

Monoclonal antibodies? So passé. Cancer metabolism drugs are emerging as the therapeutic to watch, or so says Cornerstone Pharmaceuticals CEO Steve Cardechi. Cornerstone’s approach is to develop anticancer drugs that target…


Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication

Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication

December 11, 2014 7:09 pm by | 0 Comments

A lot of hopes were pinned on using dexpramipexole to treat those with ALS. But it the small molecule drug, thought to maintain mitochondrial function, flopped in Biogen Idec’s Phase 3 trials…